九洲藥業(603456.SH)擬投資16億元建設CDMO及製劑基地項目
格隆匯11月5日丨九洲藥業(603456.SH)公佈,根據公司發展戰略,經公司董事會研究,公司決定在浙江省杭州錢塘新區醫藥港小鎮投資建設CDMO及製劑基地項目,項目將新建小分子及大分子創新藥CDMO(研發生產服務)基地和製劑研發生產中心。公司已與杭州錢塘新區管理委員會就投資協議的主要條款達成一致,協議尚需經公司股東大會審議通過方可生效。
項目總投資約16億元,分二期投資建設,一期項目總投資約10億元,二期項目總投資約6億元。項目擬選址杭州醫藥港小鎮內,一期項目用地約30畝,土地使用年限為50年,二期項目用地約40畝。雙方明確本項目所供土地為工業用地,按照國家有關規定,通過合法程序出讓土地。實際面積以《國有建設用地使用權出讓合同》載明的為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.